Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.

ABSTRACT:

Aims

Klotho, an essential co-receptor for fibroblast growth factor (FGF)-23, has potentially beneficial inhibitory effects on the renin-angiotensin system. Limited data exist on the prognostic value of Klotho and FGF-23 levels in combination or their ability to predict benefit from angiotensin-converting enzyme (ACE) inhibition.

Methods and results

A total of 3555 patients with stable ischaemic heart disease and left ventricular ejection fraction > 40% enrolled in the PEACE trial of trandolapril vs. placebo had Klotho levels drawn at randomization. Patients were characterized by quartiles of Klotho and FGF-23 concentrations. Six-year Kaplan-Meier rates and adjusted risk were calculated in the placebo arm for the composite of cardiovascular (CV) death or hospitalization for h

SUBMITTER: Bergmark BA 

PROVIDER: S-EPMC6458082 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature